Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Iain Ross, Steven Paul, Mark Levin

Premium

Biotech firm Amarantus Bioscience has appointed Iain Ross to its board of directors.

Ross is currently chairman of Ark Therapeutics and Biomer Technology. He is also a non-executive director of expressed RNAi firm Benitec Biopharma, and previously served as chairman of Silence Therapeutics.


Voyager Therapeutics has named Steven Paul, its interim president of research and development, as its new CEO.

Paul replaces Third Rock Venture partner Mark Levin, who served as the startup's interim CEO following the venture capital company's investment in Voyager earlier this year. Levin has now become Voyager's chairman.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.